The company gained an important position in the US pharmaceuticals market in the 1970s, when it acquired Cutter Laboratories Inc. in 1974 and ... Bayer Cross corporate logo. This was under the ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

(MENAFN- JCN NewsWire) Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" TOKYO, Nov 5 ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...